Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans (Q43878871)

27 November 2017

title

Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans (English)

1 reference

27 November 2017

1 reference

ChEBI release 2020-05-28

1 reference

Jim X Sun

1

1 reference

27 November 2017

Robert Niecestro

2

1 reference

27 November 2017

Gale Phillips

3

1 reference

27 November 2017

Jason Shen

4

1 reference

27 November 2017

Peter Lukacsko

5

1 reference

27 November 2017

Lawrence Friedhoff

6

1 reference

27 November 2017

publication date

1 February 2002

1 reference

The Journal of Clinical Pharmacology

27 November 2017

published in

1 reference

27 November 2017

volume

42

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

198-204

1 reference

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Discovery, biochemistry and biology of lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Biotransformation enzymes in human intestine: critical low levels in the colon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700222011111

10.1177/00912700222011111

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference